RE:RE:RE:Big pharma is set to keep signing bigger deals in 2024 How much of that $1.37 trillion in "fiepower"can the top 25 biopharmas be expected to spend in 2024?
Many of the world’s top pharmaceutical firms are seeking deals to transform often aging drug pipelines, and have billions of dollars to spend on doing so.
“The prospect of further M&A activity looks strong this year,” said Ailsa Craig, co-lead manager of the International Biotechnology Trust. “Patent expiries among the larger pharma players continue to be a pressing issue and they will continue to look towards the biotech sector for opportunities to plug the holes in their product shelves and pipelines.”
Big names set to lose patent protection for some of their key drugs include Merck & Co. and its top-selling cancer medicine Keytruda, as well as AstraZeneca, Pfizer and Bristol-Myers Squibb Co.
$200 billion of pharma companies sales will need to be replaced over this decade, according to Alex Hunter, global equity analyst at Sarasin & Partners. “The necessity to develop new drugs, both internally and through M&A, will still be a priority.”